Sentence examples for trials were calculated with from inspiring English sources

Pain reduction (the difference between treatment and control groups at the end of trials) and pain relief (the change in pain from baseline to the end of trials) were calculated with mean differences (MD) and 95 %-Confidence intervals (95 % CI).

Estimation of sample sizes for future trials were calculated (using Stata) with 80% power and 5% 2-tailed significance using the mean difference in the rate of change between groups for each DTI metric and neuropsychological score, and whole brain atrophy, using the BBSI, to detect a 20, 30, 40, and 50% reduction in yearly change.

Note that, since the mean I-DE and E-DE of the cursor-feedback trials were calculated by selecting the trial with the same visual target as the catch trial (0° and 60° in the pre- and post-training phases, respectively), we could assume that the observed differences were caused by the difference in the trial type, not by the difference in the reaching direction.

Corresponding means of the trials were calculated thereafter.

Weighted mean differences with 95% CIs were selected to describe the mean differences in statin treatment; statistical heterogeneity among the trials was calculated using I² statistics (with 95% CIs) derived from Cochran's Q(100×(Q df/Q)) (χ test).

Similarly, the "D R" criteria for each simulated trial were calculated and contrasted with the true value (ED*50) used in the simulation, after back-transformation to the real domain: The rate at which a design resulted in good D R information was then computed by summing the number of good D R and dividing by the number of trials (9,999).

Each participant performed three trials; the average of the trials was calculated prior to analysis.

The mean time of the three trials was calculated.

The mean CSP duration of five rectified trials was calculated.

Hydrogen bonds were calculated with HBPLUS [19].

Intensities were calculated with Graph Pad Prism.